Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

This trial is no longer accepting participants. For information/assistance in finding a trial that is right for you, please call Cancer AnswerLine at 800-865-1125.